Market Overview

24/7 Market News – Keep an eye on last week's Biotech IPOs

Share:
Pliant Therapeutics (NASDAQ:PLRX) began trading Wednesday, followed by Legend Biotech (NASDAQ:LEGN) and Applied Molecular Transport (NASDAQ:AMTI) on Friday. Other companies mentioned – Emmaus Life Sciences (OTCQB:EMMA)

DENVER, Colo. – June 8, 2020 – The biotech IPO calendar kicked off last week when Pliant Therapeutics (NASDAQ:PLRX) began trading Wednesday, after pricing its initial public offering at $16 per share. All trading action, during the 3 sessions, has taken place between $21 and $26. The clinical stage biopharmaceutical company sold 9 million shares, 50% more than initial plan to issue just 6 million shares, to raise $144 million.

The week ended with Legend Biotech (NASDAQ:LEGN) and Applied Molecular Transport (NASDAQ:AMTI) (AMT) exceeding their initial pricing expectations.

Legend Biotech priced its initial public offering, of 18,425,000 American depositary shares (ADSs), each representing two ordinary shares, at $23.00 per ADS, for total gross proceeds of approximately $424 million. The global clinical-stage biopharmaceutical company, which is engaged in the discovery and development of novel cell therapies for oncology and other indications, traded between $35-40 on Friday and granted the underwriters a 30-day option to purchase up to an additional 2,763,750 ADSs at the public offering price, less underwriting discounts and commissions.

AMT expects to raise $154 million, less the underwriting discounts and commissions, for the 11 million Class A shares offered on Friday. The clinical-stage biopharmaceutical company traded between $26 and $17.15, after pricing of its common stock at $14.00 per share. Additionally, AMT granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock at the initial public offering price, less fees.

Emmaus Life Sciences (OTCQB:EMMA) (ELS), a leader in sickle cell anemia disease treatment, which didn’t IPO last week, continues to build on its recent operational updates, closed Friday’s session at $ 1.60 on just over 10,000 shares.

ELS switched from a contract sales organization to its own direct sales force, which started on January 1, 2020, and continues to build its internal sales and marketing capabilities. In the first quarter of 2020, Emmaus increased sales by 10% over the preceding quarter and 39% over the same quarter of the prior year.

Connect with 24/7 Market News on social media

https://twitter.com/247MarketNewsHQ

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News

As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information.  24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:

24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

Materials in this release are informational and should never be considered research. You must do your own due diligence by reading all available public information. This release is a corporate public statement, and believed to be reliable. The principle and editor of 24/7 currently owns no shares of the aforementioned companies, but has the right to buy and sell at any time of his choosing which could be viewed as a conflict of interest. 24/7 makes no representations and warranties to the completeness of materials provided and are subject to change without notice. 24/7 is not responsible for any gains or losses which result from our opinions or coverage expressed in our emails or our site and readers are cautioned that investing has risks and you may lose all or a portion of your money.

For further information on 24/7 Market News, please go to www.247marketnews.com 

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

24/7 Market News

Editor@247marketnews.com

Media Contact
Company Name: 24/7 Market News
Contact Person: Editor
Email: Send Email
Phone: 720.989.9923
Country: United States
Website: https://www.247marketnews.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: 24/7 Market News – Keep an eye on last week's Biotech IPOs

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com